Schizophrenia News and Research RSS Feed - Schizophrenia News and Research

Schizophrenia is a chronic debilitating disorder which affects more than two million Americans, and millions more worldwide. While significant progress has been made in understanding the disease and developing treatments, there remains a significant unmet medical need. More than 50% of patients switch their medication in a given year due to either poor response or the experience of adverse events.
ADDF awards grant to support initiation of AGB101 Phase 3 trial for aMCI treatment

ADDF awards grant to support initiation of AGB101 Phase 3 trial for aMCI treatment

The Alzheimer's Drug Discovery Foundation announced today a $900,000 grant to AgeneBio, a pharmaceutical company developing innovative therapies for neurologic and psychiatric diseases. The grant will support the initiation of an FDA-registered Phase 3 clinical trial of AGB101, a new therapeutic treatment for amnestic mild cognitive impairment (aMCI). [More]
Heptares Therapeutics announces recipients of Malcolm Campbell Memorial Prize for 2015

Heptares Therapeutics announces recipients of Malcolm Campbell Memorial Prize for 2015

Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company, is delighted to announce that the Malcolm Campbell Memorial Prize for 2015 has been awarded to Miles Congreve (Vice President of Chemistry), Fiona Marshall (Chief Scientific Officer and co-founder) and Malcolm Weir (Chief Executive Officer and co-founder) for the seminal contributions to GPCR drug discovery made by Heptares Therapeutics since the company was founded in 2007. [More]
International study identifies genetic factors that influence the size of brain structures

International study identifies genetic factors that influence the size of brain structures

An international study, which included researchers from NUI Galway, has identified significant genetic factors that influence the size of structures within the brain. It is hoped these new insights may help scientists better understand disorders such as schizophrenia, Alzheimer's disease and epilepsy. [More]
Heptares Therapeutics, AstraZeneca report significant progress in drug discovery collaboration

Heptares Therapeutics, AstraZeneca report significant progress in drug discovery collaboration

Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company, announces significant progress in its drug discovery collaboration with AstraZeneca. [More]
Hallucinations linked to self-destructive thoughts among adolescents with psychological symptoms

Hallucinations linked to self-destructive thoughts among adolescents with psychological symptoms

Visual distortions and hallucinations related to an elevated risk of psychosis are linked to self-destructive thought processes among adolescents with psychological symptoms, according to a recent Finnish study. Early indications of the risk of psychosis can usually be detected long before the onset of a full-blown disorder. [More]
Personalized approaches to treating intellectual disability

Personalized approaches to treating intellectual disability

Scientists from the Florida campus of The Scripps Research Institute have produced an approach that protects animal models against a type of genetic disruption that causes intellectual disability, including serious memory impairments and altered anxiety levels. [More]
Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson announces sales of $18.3 billion for Q4 2014

Johnson & Johnson today announced sales of $18.3 billion for the fourth quarter of 2014, a decrease of 0.6% as compared to the fourth quarter of 2013. Operational results increased 3.9% and the negative impact of currency was 4.5%. Domestic sales increased 7.4%. [More]
Researchers identify novel life-preserving circuit responsible for recognizing threats

Researchers identify novel life-preserving circuit responsible for recognizing threats

Our existence depends on a bit of evolutionary genius aptly nicknamed "fight or flight." But where in our brain does the alarm first go off, and what other parts of the brain are mobilized to express fear and remember to avoid danger in the future? [More]
Gedeon Richter, Actavis report positive top line results from cariprazine Phase III trial

Gedeon Richter, Actavis report positive top line results from cariprazine Phase III trial

Gedeon Richter Plc. and Actavis plc today announced positive results from a Phase III trial evaluating the efficacy and safety of cariprazine in the prevention of relapse in patients with schizophrenia. [More]
Venom of cone snails provides leads for possible treatment of cancer, addiction

Venom of cone snails provides leads for possible treatment of cancer, addiction

While considered a delicacy in some parts of the world, snails have found a more intriguing use to scientists and the medical profession offering a plethora of research possibilities. Cone snails are marine mollusks, just as conch, octopi and squid, but they capture their prey using venom. [More]
State and federal prisoners not receiving adequate mental health care

State and federal prisoners not receiving adequate mental health care

A significant portion of state and federal prisoners are not receiving treatment for mental health conditions, according to research by The University of Texas Health Science Center at Houston School of Public Health. [More]
CET ‘feasible’ in schizophrenia patients with substance misuse

CET ‘feasible’ in schizophrenia patients with substance misuse

Patients with schizophrenia and comorbid substance abuse diagnoses are able to benefit from cognitive enhancement therapy, preliminary research suggests. [More]

Longitudinal course of schizophrenia negative symptoms revealed

Schizophrenia negative symptoms are relatively stable in the first year for most patients after they begin antipsychotic medication but research suggests around a quarter will experience exacerbation or relapse. [More]
Comorbid OCD not uncommon in bipolar disorder

Comorbid OCD not uncommon in bipolar disorder

Co-occurrence of obsessive compulsive disorder in patients with bipolar disorder type I is not uncommon and is associated with increased functional disability, research findings indicate. [More]
McGill University researchers identify network of complex neurons in the brain

McGill University researchers identify network of complex neurons in the brain

Our ability to pay attention to certain things while ignoring distractions determines how good we are at a given task, whether it is driving a car or doing brain surgery. A research team at McGill University has for the first time convincingly identified a network of neurons in a particular area of the brain, the lateral prefrontal cortex, that interact with one another to promptly filter visual information while at the same time ignoring distractions. It's a discovery with potentially far reaching implications for people who suffer from diseases such as autism, ADHD and schizophrenia. [More]
FDA receives Actavis' NDA resubmission for cariprazine

FDA receives Actavis' NDA resubmission for cariprazine

Actavis plc (NYSE: ACT) and Gedeon Richter Plc. today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of Actavis' New Drug Application (NDA) resubmission for its atypical antipsychotic cariprazine, a potent dopamine D3/D2 receptor partial agonist with preferential binding to D3 receptors. [More]
LIBD announces significant advances in identifying causes of schizophrenia, brain disorders

LIBD announces significant advances in identifying causes of schizophrenia, brain disorders

The Lieber Institute for Brain Development (LIBD) announces significant advances in identifying the causes of schizophrenia and related developmental brain disorders and translating these findings into new treatment strategies. [More]
Newron, Zambon announce re-submission of safinamide NDA to FDA

Newron, Zambon announce re-submission of safinamide NDA to FDA

Newron Pharmaceuticals S.p.A., a research and development company focused on novel CNS and pain therapies, and its commercial and development partner Zambon S.p.A., an international pharmaceutical company, announced today that the NDA for safinamide has been re-submitted to the US FDA. [More]
Intriguing small molecule directs activity of key ‘clock proteins’

Intriguing small molecule directs activity of key ‘clock proteins’

In research published in Nature Communications, Thomas Burris, Ph.D., chair of pharmacological and physiological science at Saint Louis University, reports intriguing findings about a small molecule that directs the activity of key "clock proteins," offering the potential to manage circadian rhythm and treat problems that are associated with its dysfunction, like sleep and anxiety disorders. [More]

Social environment not linked to UHR psychosis transition

Research indicates that social deprivation and migrant status do not influence the risk of transition to psychosis in ultra-high-risk individuals. [More]